ZYTO announces financial results for the third quarter of 2009

ZYTO Corp (Pink Sheets:ZYTC) (www.ZYTO.com) announces an EBITDA profit of $234,021 for the third quarter of 2009, up 325% as compared to the same period last year. Total revenue for the third quarter of 2009 was $1,106,260, up from $532,548 in revenue for the third quarter of 2008.

Revenue for the nine months ended September 30, 2009 is $2,347,605, up 64 percent from the same period last year.

According to Kami Howard, CFO, “These results show the effectiveness of our focus on marketing, sales, and after-sales support. By having a back-end revenue model that increases profits for ZYTO each month, we have the ability to provide ongoing service, support, and training to facilitate our customer’s success.”

“Our business model keeps us engaged long term with our customers. As to any business, customer loyalty and retention is invaluable. We believe the current business growth, plus the anticipated growth of our products places ZYTO Corp on a strong annual growth path for the next several years,” stated Dr. Vaughn R Cook, CEO.

ZYTO has sales efforts underway in the United States, Canada, Latin America, China, South Africa, Australia, and Europe. Sales and subscription fees are the current primary sources of liquidity. ZYTO’s sales force is comprised of an in house sales staff and independent sales representatives.

Source:

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.